Tricyclic antidepressants (TCA) antibody and antigen (hapten, BSA/OVA conjugated)

Diagnostic anti-Tricyclic antidepressants (TCA) antibodies (anti-Tricyclic antidepressants, anti-TCA) and diagnostic hapten-carrier conjugates BSA-Tricyclic antidepressants (TCA), OVA-Tricyclic antidepressants (TCA), KLH-Tricyclic antidepressants (TCA) antigens for Neurodegenerative diseases/Pain TCA detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Target products collectionGo to Neurodegenerative diseases diagnostics products collection>>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-243-Ag01BSA-Tricyclic antidepressants (TCA)$756.00
GMP-SMT-243-Ag02OVA-Tricyclic antidepressants (TCA)$756.00
GMP-SMT-243-Ab01Anti-human Tricyclic antidepressants (TCA) mouse monoclonal antibody (mAb)$1953.00
GMP-SMT-243-Ab02Anti-human Tricyclic antidepressants (TCA) human monoclonal antibody (mAb)$1953.00

Size: 1mg | 10mg | 100mg



Product Description

BSA-Tricyclic antidepressants (TCA)

Cat No.GMP-SMT-243-Ag01
Product NameBSA-Tricyclic antidepressants (TCA)
TargetTricyclic antidepressants (TCA)
Expression platformSynthetic
Bioactivity validationTricyclic antidepressants (TCA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in TCA level test of Neurodegenerative diseases/Pain and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Tricyclic antidepressants (TCA) / OVA-Tricyclic antidepressants (TCA) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

OVA-Tricyclic antidepressants (TCA)

Cat No.GMP-SMT-243-Ag02
Product NameOVA-Tricyclic antidepressants (TCA)
TargetTricyclic antidepressants (TCA)
Expression platformSynthetic
Bioactivity validationTricyclic antidepressants (TCA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in TCA level test of Neurodegenerative diseases/Pain and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Tricyclic antidepressants (TCA) / OVA-Tricyclic antidepressants (TCA) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Tricyclic antidepressants (TCA) mouse monoclonal antibody (mAb)

Cat No.GMP-SMT-243-Ab01
Product NameAnti-human Tricyclic antidepressants (TCA) mouse monoclonal antibody (mAb)
TargetTricyclic antidepressants (TCA)
Expression platformhybridoma
IsotypesMouse IgG
Bioactivity validationTricyclic antidepressants (TCA) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Tricyclic antidepressants (TCA) antibodies in TCA level test of Neurodegenerative diseases/Pain and related syndrome evaluation.
TagmFc
Products descriptionAnti-human Tricyclic antidepressants (TCA) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Tricyclic antidepressants (TCA) human monoclonal antibody (mAb)

Cat No.GMP-SMT-243-Ab02
Product NameAnti-human Tricyclic antidepressants (TCA) human monoclonal antibody (mAb)
TargetTricyclic antidepressants (TCA)
Expression platformhybridoma
IsotypesHuman IgG1
Bioactivity validationTricyclic antidepressants (TCA) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Tricyclic antidepressants (TCA) antibodies in TCA level test of Neurodegenerative diseases/Pain and related syndrome evaluation.
TaghFc
Products descriptionAnti-human Tricyclic antidepressants (TCA) mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO.
PurityPurity: ≥95% (SDS-PAGE)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationSupplied as a 0.2 μM filtered solution of PBS, PH7.4.
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Target/Biomarker information


    1. Tricyclic Antidepressants (TCA): Comprehensive Overview and IVD Application

    Tricyclic Antidepressants (TCAs) represent a fundamental class of psychotherapeutic agents that have been instrumental in the management of depressive disorders, chronic neuropathic pain, and a spectrum of mood disorders. Mechanistically, TCAs exert their therapeutic effects by inhibiting the reuptake of central neurotransmitters, notably serotonin and norepinephrine, at synaptic junctions. This action results in increased neurotransmitter availability within the central nervous system, thereby ameliorating depressive symptoms and alleviating pain. Despite the emergence of newer pharmacological alternatives with more favorable side effect profiles, TCAs maintain a vital position in therapeutic protocols, particularly for patients who do not respond adequately to other antidepressants.

    The application of Tricyclic Antidepressants in In Vitro Diagnostics (IVD) is centered around their quantification for Therapeutic Drug Monitoring (TDM). The clinical utility of TDM in the context of TCA administration is multifaceted. Primarily, it serves to ensure that drug concentrations remain within a therapeutic range that maximizes efficacy while minimizing the risk of adverse effects. The necessity for such monitoring stems from TCAs' narrow therapeutic index and the considerable inter-individual variability in their pharmacokinetics and pharmacodynamics. Accurate measurement of TCA levels in blood or plasma samples is therefore critical for individualizing treatment regimens, optimizing therapeutic outcomes, and safeguarding patient well-being.

    Our biopharmaceutical company specializes in providing state-of-the-art anti-small molecule antibodies and competitive antigens tailored for the detection of TCAs in clinical samples. These reagents are pivotal for the development of highly sensitive and specific immunoassays, enabling the precise quantification of TCA concentrations. By facilitating robust TDM practices, our products play a crucial role in advancing personalized medicine and enhancing the quality of care for patients undergoing TCA therapy.

    2. The Imperative for Measuring Tricyclic Antidepressants (TCA)

    The rationale for the meticulous measurement of Tricyclic Antidepressants encompasses several critical aspects of patient care and treatment optimization. Foremost among these is the imperative of Therapeutic Drug Monitoring (TDM). TDM of TCAs is integral for adjusting dosages to achieve desired therapeutic effects without crossing into the realm of toxicity. This balancing act is particularly challenging given the narrow therapeutic window of TCAs and the broad variability in how patients metabolize these drugs. Effective TDM can dramatically reduce the incidence of adverse drug reactions, which can range from mild anticholinergic effects to severe cardiotoxicity in cases of overdose.

    Additionally, accurate TCA quantification enables personalized treatment strategies. Genetic differences among individuals can significantly impact the metabolism of TCAs, leading to divergent therapeutic responses. By measuring TCA levels, healthcare providers can tailor treatments to the metabolic profile of each patient, thereby enhancing treatment efficacy and patient satisfaction.

    Monitoring TCA levels also plays a pivotal role in identifying non-compliance, a common challenge in managing chronic conditions like depression. Through quantitative analysis, clinicians can confirm whether patients are adhering to their prescribed medication regimens, facilitating timely interventions to address non-compliance issues.

    Our portfolio of anti-small molecule antibodies and competitive antigens for TCA detection embodies the cutting edge of IVD technology. These products are essential for the development of reliable, accurate assays that are critical for effective TDM, the realization of personalized medicine, and the overall improvement of therapeutic outcomes for patients treated with TCAs.

    This expanded description delves deeper into the scientific and clinical nuances of TCAs and their pivotal role in IVD, highlighting the advanced capabilities of your company's products in supporting personalized medicine and improving patient care through precise therapeutic drug monitoring.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.